Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 1 Dec 2009

Mancl Erin E, Kolesar Jill M, Vermeulen Lee C

Abstract excerpt

PURPOSE: The clinical and economic value of screening for Kras mutations as predictors of response to cetuximab and panitumumab are reviewed. SUMMARY: Epidermal growth factor receptor (EGFR) inhibitors cetuximab and panitumumab are agents currently used in the treatment of metastatic colorectal c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Neoplasm Metastasis

Share to Panitumumab

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19923311
DOI: 10.2146/ajhp090036

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19923311-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.PMID 19923311Read ↗

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.Semantic proximity Read ↗

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Semantic proximity Read ↗

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Semantic proximity Read ↗

Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.Semantic proximity Read ↗

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.Semantic proximity Read ↗

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.